Key Highlights

  • Bumble (NASDAQ:BMBL) rose 132.88% over the month to USD 5.99, ahead of Katapult at 113.46%, Silence Therapeutics at 95.21%, Portillo's at 85.98% and Universal Logistics at 81.02%, among 1,259 small caps screened.
  • Ithaca Holdings agreed to pay USD 6.05 per Class A share in cash, about USD 1.3 billion, a premium of roughly 138% to the October 9, 2026 unaffected close, which leaves a gap of about 1.0% (calculated).
  • A Phase 2 trial on August 10, 2026 produced an 88% clinical response for Silence Therapeutics (NASDAQ:SLN) versus 19% for placebo, and the shares have risen 219.14% year to date and 188.39% over six months.
  • Katapult (NASDAQ:KPLT) shows 49.14% over three months against 113.46% over one, and Portillo's latest session added 20.46% with no catalyst identified.

Bumble (NASDAQ:BMBL): A USD 6.05 Cash Take-Private Offer Re-Rates the Stock Toward the Bid

Bumble (NASDAQ:BMBL) closed at USD 5.99 on November 5, 2026, up 132.88% over a month and first among 1,259 small caps screened. The driver is a take-private agreement: Ithaca Holdings will buy the company for USD 6.05 per Class A share in cash, a deal worth about USD 1.3 billion and a premium of about 138% to the October 9, 2026 unaffected close. Published coverage dated October 13, 2026 had already reported buyout talks and a jump of nearly 50% in a single session. Once a cash bid is on the table, the shares tend to track the offer rather than earnings, which is why the one-week gain is only 0.25%. The fundamentals were weak, with second quarter Revenue down 15.2% to USD 210.5 million and paying users down 16.4% to 3.2 million. The gap to the offer is USD 0.06, a calculated 1.0%. If the deal failed, the price could slide toward about USD 2.54 (calculated). Closing timing was not specified, and a small number of trades can move the price.

Katapult (NASDAQ:KPLT): A Pending Merger and a Fresh Month of Gains Without a Named Trigger

Katapult (NASDAQ:KPLT) closed at USD 9.52 on November 5, 2026, up 113.46% over a month and second on the list, although it fell 5.32% in the latest session. The month has no identified catalyst, so the points below are general context rather than a confirmed cause. A pending all-stock combination with The Aaron's Company and CCF Holdings, announced in December 2025 and backed by shareholders on August 6, 2026, changes the Business mix and could draw event-driven funds. First quarter revenue reached USD 79.0 million, up 9.8% but below the USD 82.0 million consensus, while diluted EPS of USD 0.07 beat a consensus loss of USD 0.04. Third quarter results are due November 12, 2026. Gains of 49.14% over three months, 36.51% over six months and 48.21% year to date show that most of the run arrived in the last month, which raises Reversal risk. The exchange ratio was not confirmed, and a small number of trades can move the price.

Silence Therapeutics (NASDAQ:SLN): Phase 2 Divesiran Data Set the Base for a 219.14% Year

Silence Therapeutics (NASDAQ:SLN) closed at USD 19.76, up 95.21% over a month and 219.14% year to date, with no separate catalyst identified for the month. The event that matters is the August 10, 2026 Phase 2 SANRECO readout of divesiran in polycythemia vera, which showed an 88% clinical response against 19% for placebo, and the stock rose 35.3% that session. A randomized win in a rare blood disease lifts approval odds, brings a Phase 3 study into view and can attract partners and momentum buyers, with a Phase 3 start planned for the first half of 2027. Cash was USD 72.1 million at June 30, 2026 against a six-month net loss of USD 27.2 million, so an Equity raise is a live risk. Revenue was zero in the quarter and 141,739,180 shares were outstanding. After a 188.39% six-month run, the shares could reverse, and spreads can be wide.

Portillo's (NASDAQ:PTLO): Restaurant Rebound Runs Ahead of Unconfirmed Third Quarter Figures

Portillo's (NASDAQ:PTLO) closed at USD 6.57 after a 20.46% gain in the latest session, with 44.29% over one week and 85.98% over one month. No catalyst was identified, and third quarter figures, due in a webcast on November 5, 2026, were not confirmed. A restaurant stock near the low end of its range can rebound when short sellers cover or when expectations sit low enough to be beaten. The shares closed at USD 4.21 on October 23, 2026, so USD 6.57 is about 56% higher (calculated), implying a Market Value near USD 499 million (calculated) against USD 319.72 million. Second quarter revenue rose 5.6% to USD 199.0 million, yet same-restaurant sales fell 1.2% and Net Income dropped 28.8% to USD 7.2 million. Forward P/E stood at 19.77, long-term Debt at USD 235.2 million, and the 52-week range runs from USD 3.29 to USD 6.69. Thin trading can move the price in both directions, and the gain may reverse.

Universal Logistics (NASDAQ:ULH): Quarterly Swing From Loss to Profit Carries the Monthly Rally

Universal Logistics (NASDAQ:ULH) rose 81.02% over a month and 83.75% over a week to USD 31.72, placing it fifth on the one-month list. No catalyst beyond third quarter results on October 29, 2026 was identified, and those results showed net income of USD 18.142 million against a loss of USD 117.938 million a year earlier, with EPS of USD 0.69. A swing from loss to profit usually forces analysts to lift forecasts quickly, so the turnaround is the core of the story. Gains of 136.33% over six months and 108.38% year to date show that the run began before that report. The shares closed at USD 16.74 on October 23, 2026, which puts the current quote about 89% higher (calculated) and above the 52-week high of USD 25.80, implying roughly USD 836 million of market value (calculated). Revenue slipped 0.7% (calculated), Intermodal fell 17.9%, and net debt of about USD 678.1 million compares with USD 15.3 million of cash. Volume was 41,101 shares on October 23, 2026, and spreads can be wide, so the move may reverse.

Where Things Stand

A cash Takeover explains the top name. Bumble (NASDAQ:BMBL) sits under a USD 6.05 offer, which is why its one-week gain was small. Katapult (NASDAQ:KPLT) has no single confirmed catalyst. Portillo's (NASDAQ:PTLO) has none either. Silence Therapeutics (NASDAQ:SLN) followed Phase 2 data. Universal Logistics (NASDAQ:ULH) tracked a swing to profit. The lists cover small caps of 300 million to 2 billion USD and mid caps of 2 billion to 10 billion USD, drawn from a published screener snapshot of November 5, 2026. Rallies on this scale can reverse because thin trading, wide spreads and stretched prices leave little cushion.